Hemoglobin A1c testing devices market seen reaching $3.53 billion by 2030

The hemoglobin A1c testing devices market is projected to grow from $2.32 billion in 2026 to $3.53 billion by 2030, driven by rising diabetes cases, home monitoring demand and digital diabetes tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - Hemoglobin A1c testing is a core tool for tracking long-term blood sugar control in diabetes care. - Rising diabetes and pre-diabetes cases are expanding demand for testing devices in clinics, labs and home settings. - The market outlook points to continued growth as care shifts toward remote monitoring and personalized management.

What happened: - The Business Research Company released a 2026 market outlook for hemoglobin A1c testing devices. - The report estimates the market will increase from $2.08 billion in 2025 to $2.32 billion in 2026. - The report forecasts the market will reach $3.53 billion by 2030. - The report projects a 11.7% CAGR from 2025 to 2026 and an 11.1% CAGR through 2030. - The release was issued Aug. 10, 2026, from London. - More information is available in the company's sample report and the full market report.

The details: - The market's recent growth has been supported by more diabetes cases, routine blood glucose monitoring, broader access to diagnostic labs and wider use of standardized testing. - Future growth is tied to home-based diabetes monitoring, AI-powered analytics, remote patient monitoring and personalized diabetes care. - The report also flags growth in point-of-care HbA1c devices, portable and handheld testers, digital connectivity, faster assays and patient-centered monitoring. - Hemoglobin A1c devices measure glycated hemoglobin, which reflects average blood sugar over time. - The devices help clinicians and patients track disease progression, adjust treatment and reduce complications. - In June 2024, the UK's National Health Service reported that England added more than 549,000 people at risk of type 2 diabetes in 2023. - The NHS said the total number of people with non-diabetic hyperglycemia registered with general practitioners reached 3,615,330, up nearly 20% from 3,065,825 in 2022.

Between the lines: - The forecast suggests diabetes monitoring is moving beyond routine testing toward continuous, connected care. - The strongest growth themes are centered on convenience, earlier intervention and more data-driven treatment decisions. - North America led the market in 2025 because of advanced healthcare infrastructure and high diabetes prevalence. - Asia-Pacific is expected to be the fastest-growing regional market during the forecast period.

What's next: - Market demand is likely to rise as more patients seek home testing and remote monitoring options. - Device makers may keep pushing portable hardware, cloud-linked platforms and quicker assays. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report package includes TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics, and updated graphics and tables. - Contact details for the report include Saumya Sahay at marketing@tbrc.info and Oliver Guirdham at The Business Research Company.

The bottom line: - HbA1c testing devices are moving from a stable diagnostic niche into a faster-growing diabetes management category, with home monitoring and connected care shaping the next phase of growth.